Tessier Jeffrey, Green Candace, Padgett Diana, Zhao Wei, Schwartz Lawrence, Hughes Molly, Hewlett Erik
University of Virginia Health Sciences Center, Box 800419, Charlottesville, VA 22908, USA.
Infect Immun. 2007 Apr;75(4):1895-903. doi: 10.1128/IAI.01632-06. Epub 2007 Jan 29.
Bacillus anthracis edema toxin (ET), composed of protective antigen and an adenylate cyclase edema factor (EF), elicits edema in host tissues, but the target cells and events leading from EF-mediated cyclic-AMP production to edema are unknown. We evaluated the direct effect of ET on several cell types in vitro and tested the possibility that mediators of vascular leakage, such as histamine, contribute to edema in rabbits given intradermal ET. ET increased the transendothelial electrical resistance of endothelial monolayers, a response that is mechanistically inconsistent with the in vivo vascular leakage induced by ET. Screening of several drugs by intradermal treatment prior to toxin injection demonstrated reduced ET-induced vascular leakage with a cyclo-oxygenase inhibitor (indomethacin), agents that interfere with histamine (pyrilamine or cromolyn), or a neurokinin antagonist (spantide). Systemic administration of indomethacin or celecoxib (cyclo-oxygenase inhibitors), pyrilamine, aprepitant (a neurokinin 1 receptor antagonist), or indomethacin with pyrilamine significantly reduced vascular leakage associated with ET. Although the effects of pyrilamine, cromolyn, or aprepitant on ET-induced vascular leakage suggest a possible role for mast cells (MC) and sensory neurons in ET-induced edema, ET did not elicit degranulation of human skin MC or substance P release from NT2N cells in vitro. Our results indicate that ET, acting indirectly or directly on a target yet to be identified, stimulates the production/release of multiple inflammatory mediators, specifically neurokinins, prostanoids, and histamine. These mediators, individually and through complex interactions, increase vascular permeability, and interventions directed at these mediators may benefit hosts infected with B. anthracis.
炭疽芽孢杆菌水肿毒素(ET)由保护性抗原和腺苷酸环化酶水肿因子(EF)组成,可在宿主组织中引发水肿,但从EF介导的环磷酸腺苷产生到水肿的靶细胞和相关事件尚不清楚。我们在体外评估了ET对几种细胞类型的直接作用,并测试了血管渗漏介质(如组胺)是否会导致皮内注射ET的家兔出现水肿。ET增加了内皮细胞单层的跨内皮电阻,这一反应在机制上与ET诱导的体内血管渗漏不一致。在注射毒素前进行皮内治疗,筛选几种药物,结果显示,使用环氧化酶抑制剂(吲哚美辛)、干扰组胺的药物(吡苄明或色甘酸)或神经激肽拮抗剂(spantide)可减少ET诱导的血管渗漏。全身给予吲哚美辛或塞来昔布(环氧化酶抑制剂)、吡苄明、阿瑞匹坦(神经激肽1受体拮抗剂)或吲哚美辛与吡苄明联用,可显著减少与ET相关的血管渗漏。尽管吡苄明、色甘酸或阿瑞匹坦对ET诱导的血管渗漏的影响表明肥大细胞(MC)和感觉神经元在ET诱导的水肿中可能发挥作用,但ET在体外并未引起人皮肤MC脱颗粒或NT2N细胞释放P物质。我们的结果表明,ET直接或间接作用于尚未确定的靶点,刺激多种炎症介质的产生/释放,特别是神经激肽、前列腺素和组胺。这些介质单独或通过复杂的相互作用增加血管通透性,针对这些介质的干预措施可能对感染炭疽芽孢杆菌的宿主有益。